1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
3 bought · 1 sold
Latest: purchase, 2025-12-18
Astrazeneca insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ASTRAZENECA PLC insiders sold a net $2.2M of stock across 2 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 20, 2026.
The trade is 0.1% of the 19,287 shares held after it.
No other insider bought within 30 days.
800 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sharma Mani bought about $3.2K of AZN on Aug 8, 2026, the largest insider purchase at the company on our record; 800 funds added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 61.7% of the 19,262 shares held after it.
No other insider sold within 30 days.
800 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sharma Mani sold about $2.2M of AZN on May 20, 2026, the largest insider sale at the company on our record; 800 funds added in the latest 13F quarter.
2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
AZN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AZN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Parnassus Value Select ETF
$1.2M position · as of 2026-06-30
4.8%
AlphaCentric Life Sciences and Healthcare Fund
$2.2M position · as of 2026-06-30
4.6%
CRAWFORD LARGE CAP DIVIDEND FUND
$2.4M position · as of 2026-06-30
4.1%
COMMONWEALTH GLOBAL FUND
$636.1K position · as of 2026-07-31
3.5%
John Hancock Disciplined Value International Select ETF
$22.0M position · as of 2026-06-30
3.1%
Invesco V.I. Health Care Fund
$4.7M position · as of 2026-06-30
2.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1126 registered trials, 496 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
251
Phase 1
53 active
152
Phase 2
67 active
257
Phase 3
170 active
34
Phase 4
12 active
1
Early Phase 1
0 active
370
Not applicable
149 active
61
Multi-phase
45 active
What changed recently
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Ve
2026-10-27 · Recruiting → Completed
,
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerab
2026-10-24 · Recruiting → Active Not Recruiting
PHASE1,PHASE2
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Ne
2026-10-24 · Recruiting → Active Not Recruiting
,
Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertens
2026-10-23 · Completion moved 2026-09-30 → 2026-11-30
,
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and
2026-10-23 · Completion moved 2026-11-11 → 2027-05-03
Phase 3
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Ca
2026-10-23 · Recruiting → Active Not Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.2M sold by insiders over 180 days, 800 funds added last quarter, 3 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
AZN ranks highest on risk and compliance (91st percentile) and institutional and government (88th), and lowest on insider conviction (42nd), among Pharma & Biotech peers.
Insider conviction
42
Inputs
Net Form 4 buying (codes P and S), 180d-$2.2M · 28 pct, sector of 428
Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
88
Inputs
Funds adding, latest quarter800 · 99 pct, sector of 698
Congress net buyers, 365d2 · 98 pct, sector of 49
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$660K · 67 pct, sector of 133
Risk and compliance
91
Inputs
Short interest, % of float+0.2% · 91 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AZN filings, in plain words
Are Astrazeneca insiders buying or selling AZN?
In the 180 days to 2026-10-27, Astrazeneca insiders were net sellers, a net $2.2M: $3.2K of purchases and $2.2M of sales reported on Form 4, by 1 buyer and 1 seller.
Have members of Congress traded AZN?
Yes. In the year to 2026-10-27, 3 House members disclosed buying AZN and 1 House member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-12-18.
Read the full summary
In the 180 days to 2026-10-27, Astrazeneca insiders were net sellers of AZN, a net $2.2M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Sales outweighed purchases more than tenfold by value. In the year to 2026-10-27, 3 members of Congress disclosed buying AZN and 1 member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-12-18. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
